JP2022525007A5 - - Google Patents
Info
- Publication number
- JP2022525007A5 JP2022525007A5 JP2021552728A JP2021552728A JP2022525007A5 JP 2022525007 A5 JP2022525007 A5 JP 2022525007A5 JP 2021552728 A JP2021552728 A JP 2021552728A JP 2021552728 A JP2021552728 A JP 2021552728A JP 2022525007 A5 JP2022525007 A5 JP 2022525007A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- βcd
- sbe
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814028P | 2019-03-05 | 2019-03-05 | |
| US62/814,028 | 2019-03-05 | ||
| PCT/US2020/020805 WO2020180872A1 (en) | 2019-03-05 | 2020-03-03 | Compositions of matter with activity to remove lipofuscin from retinal cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525007A JP2022525007A (ja) | 2022-05-11 |
| JP2022525007A5 true JP2022525007A5 (https=) | 2023-03-08 |
| JP7573881B2 JP7573881B2 (ja) | 2024-10-28 |
Family
ID=72337111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552728A Active JP7573881B2 (ja) | 2019-03-05 | 2020-03-03 | 網膜細胞からリポフスチンを除去する活性を有する組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220118002A1 (https=) |
| EP (1) | EP3934660A4 (https=) |
| JP (1) | JP7573881B2 (https=) |
| KR (1) | KR20210142651A (https=) |
| CN (1) | CN113747902A (https=) |
| AU (1) | AU2020232266A1 (https=) |
| BR (1) | BR112021017529A2 (https=) |
| CA (1) | CA3132466A1 (https=) |
| CO (1) | CO2021012267A2 (https=) |
| EA (1) | EA202192183A1 (https=) |
| IL (1) | IL286002A (https=) |
| MX (1) | MX2021010650A (https=) |
| PH (1) | PH12021552131A1 (https=) |
| SG (1) | SG11202109541YA (https=) |
| WO (1) | WO2020180872A1 (https=) |
| ZA (1) | ZA202106559B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3205822A1 (en) * | 2021-01-22 | 2022-07-28 | Marcelo M. NOCIARI | Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity |
| AU2023420130A1 (en) * | 2022-12-30 | 2025-08-14 | Cornell University | Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases |
| CN116253809B (zh) * | 2023-04-19 | 2024-11-05 | 广州润虹医药科技股份有限公司 | 一种去除壳聚糖中内毒素的方法 |
| WO2025147228A1 (en) * | 2024-01-02 | 2025-07-10 | Alkeus Pharmaceuticals, Inc. | Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US8679511B2 (en) * | 2009-10-01 | 2014-03-25 | Duquesne University of the Holy Spririt | In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts |
| WO2011072141A1 (en) * | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| US10463687B2 (en) * | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
| KR101423631B1 (ko) * | 2012-08-17 | 2014-07-25 | 주식회사파마킹 | 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 |
| WO2014152959A1 (en) * | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| WO2016168772A1 (en) | 2015-04-17 | 2016-10-20 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| GB2556082A (en) | 2016-11-18 | 2018-05-23 | Warneford Healthcare Ltd | Ophthalmic composition |
-
2020
- 2020-03-03 AU AU2020232266A patent/AU2020232266A1/en not_active Abandoned
- 2020-03-03 US US17/436,023 patent/US20220118002A1/en active Pending
- 2020-03-03 WO PCT/US2020/020805 patent/WO2020180872A1/en not_active Ceased
- 2020-03-03 BR BR112021017529A patent/BR112021017529A2/pt not_active Application Discontinuation
- 2020-03-03 EP EP20767194.2A patent/EP3934660A4/en active Pending
- 2020-03-03 JP JP2021552728A patent/JP7573881B2/ja active Active
- 2020-03-03 EA EA202192183A patent/EA202192183A1/ru unknown
- 2020-03-03 PH PH1/2021/552131A patent/PH12021552131A1/en unknown
- 2020-03-03 KR KR1020217031603A patent/KR20210142651A/ko not_active Ceased
- 2020-03-03 CN CN202080031946.8A patent/CN113747902A/zh active Pending
- 2020-03-03 CA CA3132466A patent/CA3132466A1/en active Pending
- 2020-03-03 MX MX2021010650A patent/MX2021010650A/es unknown
- 2020-03-03 SG SG11202109541YA patent/SG11202109541YA/en unknown
-
2021
- 2021-08-31 IL IL286002A patent/IL286002A/en unknown
- 2021-09-07 ZA ZA2021/06559A patent/ZA202106559B/en unknown
- 2021-09-20 CO CONC2021/0012267A patent/CO2021012267A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525007A5 (https=) | ||
| Srinivasarao et al. | Fundamentals, challenges, and nanomedicine‐based solutions for ocular diseases | |
| Hathout et al. | Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication | |
| Weng et al. | Nanotechnology-based strategies for treatment of ocular disease | |
| Kwon et al. | Potential therapeutic usage of nanomedicine for glaucoma treatment | |
| Mehra et al. | Safety and toxicity of nanomaterials for ocular drug delivery applications | |
| Sarkar et al. | Nanodiagnostics and Nanotherapeutics for age-related macular degeneration | |
| JP2017061467A5 (https=) | ||
| Maharjan et al. | Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations | |
| CN100594888C (zh) | 适用于眼科疾病治疗的药物组合物 | |
| TW201818943A (zh) | 用於眼用藥物輸送的環糊精奈米顆粒之製備 | |
| Abadia et al. | Clinical applications of dexamethasone for aged eyes | |
| Gilger et al. | Treatment of immune‐mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices | |
| JP2025016677A (ja) | 組成物 | |
| WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
| Xin et al. | Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration | |
| JP2022050551A (ja) | 炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド | |
| Qiu et al. | Dendritic oligoethylenimine decorated liposome with augmented corneal retention and permeation for efficient topical delivery of antiglaucoma drugs | |
| Pardeshi et al. | Current perspectives in nanomedicine delivery for targeted ocular therapeutics | |
| Ashique et al. | Nanotechnology: A state of the art for the management of ocular disorders—A roadmap | |
| JP2023129660A (ja) | 粘膜表面における活性薬剤の増強された輸送のための低張性ヒドロゲル製剤 | |
| Wang et al. | Nanomedicine in ophthalmology: conquering anatomical barriers and enhancing therapeutic efficacy | |
| WO2025261323A1 (zh) | 一种依维莫司眼局部给药制剂 | |
| Pignatello et al. | Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity | |
| Basu et al. | Modified thiomer-based nanomedicines in management of ocular complications: a review |